Drugs / [18F]F-RESCA-RB14
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06715826 | Sep 2024 → Nov 2026 expected | breast carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06715839 | Dec 2024 → Sep 2027 expected | appendix cancer, bile duct carcinoma, esophageal cancer, gallbladder carcinoma +4 | RenJi Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]F-RESCA-RB14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06715826 ↗ |
| Route | Other | “after \[18F\]F-RESCA-RB14 injection” NCT06715839 ↗ |